Summary

KEY INSIGHTS
WEGOVY (Semaglutide) is a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. It promotes weight loss by decreasing appetite, enhancing feelings of fullness, reducing food consumption, and lowering calorie intake.
Semaglutide has received approval from the US FDA for long-term weight management in adults who are obese or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol, to be used alongside a calorie-restricted diet and increased physical activity. The drug is currently being tested in a Phase III clinical trial for individuals with obesity and knee osteoarthritis.
The drug is developed by Novo Nordisk. Novo Nordisk AS, a subsidiary of Novo Holdings AS, is a healthcare company specializing in the discovery, development, and production of biological medicines. The company is dedicated to advancing treatments for diabetes and other serious and chronic conditions, such as hemophilia, rare endocrine diseases, human growth hormone (HGH) disorders, rare blood disorders, and obesity.
Novo Nordisk’s product range includes glucagon emergency kits, cartridges, needles, pre-filled insulin delivery systems, vials, insulin, estradiol for hormone replacement therapy, recombinant drugs for hemophilia, glucagon, and oral antidiabetic medications. The company explores innovative treatments such as WEGOVY for patients with obesity and osteoarthritis, demonstrating its potential role in managing osteoarthritis signs and symptoms. The company distributes its products through its subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia, and is headquartered in Bagsvaerd, Denmark.
MARKET POTENTIAL AND POSITIONING
WEGOVY, or semaglutide, is a GLP-1 receptor agonist that has also gained approval for weight management in individuals with obesity or those who are overweight with at least one related health condition. This medication replicates the function of the body’s natural incretin hormones, which play a role in controlling blood sugar levels post-meal. By modulating these hormone levels, semaglutide also increases satiety, thereby reducing daily calorie intake and promoting weight loss.
Currently, WEGOVY is being studied in a Phase III clinical trial to evaluate its effectiveness in patients with osteoarthritis. Recent findings from the STEP 9 study, presented at the World Congress on Osteoarthritis in April 2024, highlighted its dual benefits. Semaglutide not only induced significant weight loss but also provided substantial pain relief for patients with knee osteoarthritis and obesity.
Over a 68-week period, patients treated with semaglutide experienced a notable reduction in knee pain, with a mean decrease of 41.7 points on the WOMAC pain score, compared to a 27.5-point reduction with placebo, showing a statistically significant treatment difference of 14.1 points (P < 0.001). Additionally, semaglutide resulted in a greater weight loss of 13.7% compared to 3.2% for the placebo group, marking a significant 10.5% greater reduction in weight.
These findings position WEGOVY as a versatile treatment option in the market, not only for weight management in patients with obesity but also as a potential therapy for osteoarthritis-related knee pain, addressing two major health concerns simultaneously.
REGIONAL ANALYSIS
Inkwood Research offers an analysis of seven key markets:
• United States
• Germany
o Obesity is a key factor that may lead to osteoarthritis, particularly due to increasing pressure on joints like the knees and hips. In Germany, the increasing prevalence of obesity is linked to a rise in osteoarthritis cases, as excess body weight adds extra pressure on the joints, leading to more rapid cartilage wear and tear.
o Lack of physical activity and occupational risks are also significant contributors to osteoarthritis in Germany. Repeated stress on joints from activities like heavy labor or sports can result in injuries that increase the likelihood of developing osteoarthritis. Meanwhile, insufficient exercise can lead to muscle weakness, which may further destabilize the joints and elevate the risk of the condition.
• France
• United Kingdom
• Italy
• Spain
• Japan

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. INTRODUCTION TO THE REPORT
2. WEGOVY OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.3. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. WEGOVY MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF WEGOVY IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF WEGOVY IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF WEGOVY IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF WEGOVY IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF WEGOVY IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF WEGOVY IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF WEGOVY IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF WEGOVY IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF WEGOVY IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE